论文部分内容阅读
目的评估吉西他滨联合顺铂治疗晚期非小细胞肺癌的近期疗效和安全性。方法对33例晚期非小细胞肺癌患者采用吉西他滨1000 mg/m2,静滴,第1、8天;顺铂35 mg/m2,静滴,第1、2天。3周为1个周期,2个周期后进行一次疗效评价。结果33例患者中完全缓解(CR)0例,部分缓解(PR)14例,稳定(SD)14例,进展(PD)5例,总有效率(CR+PR)为42.4%。初治优于复治(54.2%对11.1%,P=0.030)。中位疾病进展时间(TTP)5.2个月。本方案的主要毒副作用是Ⅲ/Ⅳ度血小板减少和胃肠道反应。结论吉西他滨联合顺铂3周方案治疗晚期非小细胞肺癌患者具有良好的疗效和较低的毒副作用。
Objective To evaluate the short-term efficacy and safety of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods 33 cases of advanced non-small cell lung cancer patients with gemcitabine 1000 mg / m2, intravenous drip, on the first and eighth days; cisplatin 35 mg / m2, intravenous infusion, day 1,2. 3 weeks for a cycle, 2 cycles after a curative effect evaluation. Results Among the 33 patients, there were 0 complete remission (CR), 14 partial remission (PR), 14 stable (SD) and 5 progressive (PD) patients. The total effective rate (CR + PR) was 42.4%. Initial treatment was better than retreatment (54.2% vs 11.1%, P = 0.030). Median disease progression time (TTP) 5.2 months. The main side effects of this program is Ⅲ / Ⅳ thrombocytopenia and gastrointestinal reactions. Conclusion Gemcitabine combined with cisplatin 3 weeks regimen has a good curative effect and low toxicity in patients with advanced non-small cell lung cancer.